KALY - Kali-Extracts Develops Cannabis Treatment For Type 2 Diabetes Expected To Be $64 Billion Market
April 02 2019 - 9:03AM
InvestorsHub NewsWire
KALY - Kali-Extracts Develops
Cannabis Treatment For Type 2 Diabetes Expected To Be $64 Billion
Market
Dallas, TX -- April 2, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today unveiled its ongoing research and
development of a cannabis treatment for Type 2 Diabetes.
Kali-Extracts, through its patented cannabis extraction process, is
developing a variety of treatments for various health issues.
KALY recently published a research report on its pilot cannabis treatment for Chronic Obstructive
Pulmonary Disease (COPD). Today, KALY is beginning to
disclose its additional research and development of cannabis
extracts for additional health issues. The company currently
has ongoing cannabis extract research and development targeting
four specific health issues, COPD and Type 2 Diabetes, and two
additional health issues KALY plans to announce later this week and
next week leading up to an online presentation with more detail on
each of the treatment developments later this month. The
market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market
for COPD treatment is anticipated to reach $14 billion by 2025.
In addition to its pharmaceutical
developments, KALY is generating revenue from is patented cannabis
extraction process delivering proprietary extracts for infusion
into non-pharmaceutical commercial products. KALY announced
last week finalizing it’s all new 25 mg CBD Extract formulation for
beverage infusion. KALY’s patented extraction process already
produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC:
PURA) (“PURA”) leading EVERx CBD Sports Water. KALY has
also recently announced plans to provide commercial extraction for
Nouveau, Inc. (USOTC:
NOUV) (“NOUV”) in conjunction with NOUV’s recently announced
100-acre hemp farm.
KALY is
a health and wellness company set to generate revenue from its
patented cannabis extraction technology through overlapping
go-to-market strategies. In addition developing
pharmaceutical products internally and through partnerships, KALY
is utilizing is patented cannabis extraction process to develop
numerous wellness products both internally and through
partnerships. The first revenue generating contracts signed in
December of 2018 will be reflected in the company’s upcoming annual
report.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024